J B Chemicals & Pharmaceuticals Ltd

<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>JB Chemicals & Pharmaceuticals Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24390MH1976PLC019380</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>NSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Mr Sandeep Phadnis <br/> Designation: Company Secretary <br/> EmailId: sandeep.phadnis@jbpharma.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Mr Narayan Saraf <br/> Designation: Chief Financial Officer <br/> EmailId: secretarial@jbpharma.com</div> </div> <div> <br/> Date: 14/05/2025<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>

Audited Standalone and Consolidated Financial Results for the year ended on March 31 2025

Recommendation of Final Dividend of Rs. 7 (700%) per equity share of FV of Re. 1 each for FY 2024-25

Appointment of Non-Executive Independent Director

Re-appointment of Non-Executive Independent Director

Appointment of Secretarial Auditor

Annual Secretarial Compliance

Re-appointment of Statutory Auditors

Audited standalone and Consolidated financial results for the year ended on March 31 2025 accompanied by Auditors Report.

Press Release

Presentation

Intimation of schedule of Analysts/Institutional investors meet